2019 tumor immunotherapy summit concluded successfully in Shanghai! Promoting the coordinated development of government, industry, education and research in tumor immunotherapy

On August 18, the "2019 cancer immunotherapy leaders summit" hosted by Wanyi Medical Co., Ltd was successfully concluded at Novotel Jiantao hotel in Shanghai! The meeting was co organized by Shanghai Pudong New Area Biological Industry Association and Shanghai Zhangjiang pharmaceutical Valley public service platform Co., Ltd with the support of Shanghai Anting health care industry cluster, Shenzhen life science and Biotechnology Association, Shenzhen cell therapy Technology Association and other institutions, it presented a knowledge feast closely connecting scientific research and industry The 2019 tumor immunotherapy summit brings together more than 300 tumor immunotherapy participants, including more than 30 clinical experts, scientific researchers and excellent entrepreneurs, to discuss the innovation and development of the era of tumor immunotherapy At the beginning of the policy interpretation meeting, Fu Daxu, director of Shanghai biomedical technology industry promotion center, made an in-depth interpretation of the "development trend and supporting policies of immunocytotherapy industry" Director Fu mentioned that China has entered the transitional stage of the transformation of immune cell products Based on the emphasis on the improvement of innovation ability of biomedical industry and the complete system of R & D and manufacturing industry chain, the development of cell therapy in Shanghai has certain advantages Through the establishment of major municipal cell therapy projects, supporting the clinical research of cell therapy products, supporting the discovery and identification of new targets related to cell therapy, etc., we will strengthen the capacity-building of the whole industrial chain of cell therapy research and development in Shanghai, and form a demonstration project In March this year, the general office of the National Health Commission on the management measures for clinical research and transformation application of somatic cell therapy (Trial) (Draft for comments) made it clear that medical institutions, as the main body of responsibility, carry out clinical research on new technologies such as somatic cell therapy and obtain safety and effectiveness data At this meeting, Wang quanjun, director of the National Center for drug safety evaluation and research, Institute of toxicants and drugs, Academy of military medicine, brought a wonderful share entitled "non clinical evaluation research on car-t cell therapy products", and made in-depth understanding of relevant management requirements and guiding principles Wang quanjun mentioned that the pre clinical evaluation of car-t cell treatment products should take providing clinical effective information, ensuring clinical safety and providing monitoring indicators as the mission, and support the dose design of FIH as the purpose Clinical progress Professor Zhang Yi, director of biological treatment center of the First Affiliated Hospital of Zhengzhou University, has been engaged in tumor immunotherapy research and clinical application for more than 30 years, and has rich practical experience Focusing on the clinical application progress and management of tumor cell immunotherapy, Professor Zhang gave a wonderful speech on the current situation of tumor cell immunotherapy, the progress of car-t cell therapy for solid tumors, and the management way of immunotherapy Zhang said that the microenvironment immunosuppression of solid tumors is an important reason for the failure of car-t cells in the treatment of solid tumors Professor Gao Quanli, director of immunotherapy department and director of biological treatment center of Henan Cancer Hospital, gave a lecture entitled "PD-1 antibody combined with adoptive immunocell therapy targeting failed renal cancer" Professor Gao combined with specific cases to analyze the therapeutic effect and side effects of PD-1 antibody combined with RCAT cells Furthermore, the preliminary results of PD-1 antibody combined with r-cik cells in the treatment of renal cell carcinoma showed good efficacy and tolerable adverse reactions Professor Du Bing, director of Biochemistry and molecular biology, School of life sciences, East China Normal University, is mainly engaged in the research on the regulatory mechanism of infection, inflammation and tumor immune microenvironment Professor Du Bing made a wonderful share on the topic of "from T cells to tumor immune microenvironment: breakthrough and development of tumor immunotherapy" It is also mentioned that "like tumor cell therapy, immunotherapy is difficult to have a unified treatment method In the future research, the concept of personalized treatment will be gradually developed to carry out more targeted immunotherapy for different tumors Industrial innovation belongs to legend biology of Kingsley Biotechnology Co., Ltd It is a high-tech biotechnology company focusing on cell immunotherapy, integrating research and development, clinical development and cooperation It has made a breakthrough in the clinical research of car-t immunotherapy for multiple myeloma Dr Jiang Xinpo is responsible for the product development and analytical method development of cart products In the past year, Dr Jiang has completed the establishment of the production process and analytical method for the legendary bcmacart to enter clinical practice Focusing on "the challenges in cart process and analytical method development", Dr Jiang made an in-depth discussion on cart production process and analytical method Shanghai youcadi Biomedical Technology Co., Ltd is committed to the development and clinical application of cellular immunotherapy, especially in the field of car-t Dr Yu Lei, CEO and chief scientist, worked as a clinical surgeon in China for many years and then went to study abroad He has been engaged in virus related research and gene therapy for more than ten years and accumulated rich experience in research and development and industrial management At the same time, Dr Yu Lei is also director of the Institute of Biomedical Engineering and technology of East China Normal University Dr Yu Lei and the guests shared the wonderful lecture "progress and challenges of car-t in the treatment of malignant blood tumors" Call for the joint efforts of peers to make car-t greater Dr Tan Chang, director of gene project of lucky, has rich experience in tumor target gene screening and research, virus vector development and preparation At this meeting, we shared with the guests the theme report entitled "discussing the quality and cost balance of GMP virus vector from the perspective of the industrialization challenge of cell gene therapy" Tan Chang mentioned that the industrialization of cell gene therapy is full of challenges due to the factors of complex products, high innovation, fierce competition, slow platform construction and high investment cost The vision of Kekai gene cell & gene therapy cro / cdmo service platform is to be a full process service provider with the best understanding of cell & gene therapy, to help the industrial development, and to build a cell & gene therapy product for Chinese people Co founder of Beijing Yimiao Shenzhou Pharmaceutical Technology Co., Ltd and CMO Dr Lu Xin'an, quality president of Jinan Yiming Medical Technology Co., Ltd Dr Liu Shuangsheng, senior scientist and head of R & D Technology Department of Bosheng Ji'an Cell Technology Co., Ltd Dr Chen Yusheng, R & D department head of Shanghai Yuyan Biotechnology Co., Ltd Dr Yang Chunxia, R & D department head of China Pharmaceutical City Management Committee Investment Center Yang Hongwei, deputy director of the sub Bureau, also gave a wonderful keynote speech on the latest development of cd19car-t treatment R / RB NHL, the practice of car-t product R & D compliance based on the research and development process of biological products and the requirements of the registration data organization, the challenges and solutions of car-t industrialization, tumor specific immunotherapy: strategies and challenges, and the contribution of specialized parks to the innovation and development of large health industry On site interactive Q & A, let the audience receive goods full As an important supplier of GMP grade primary and auxiliary reagents and instruments in the industry, bio techne has developed the whole product line scheme of cell and gene therapy based on years of experience in producing high-quality products, and permeated cell and gene therapy from early scientific research discovery, cell therapy production process optimization to final industrial production stages Dr Ma Weina, manager of application science department of bio techne in China, brought the dry goods sharing entitled "optimizing work flows for exvivo cell therapy manufacturing" Fujifillmirvine scientific is a global leading high-tech company focusing on the innovative research, development and production of cell culture products In the fields of industrial cell culture, assisted reproduction, cell therapy and cytogenetics, it continues to provide high-quality, reliable products and flexible, customized excellent services for scientific research, industrial customers and clinicians all over the world Dr Feng Jian, regional manager of China, has many years of experience in animal cell culture, and has participated in a number of industrialization projects for the development of biological medicine and vaccine cell culture process Dr Feng Jian shared "chemically defined culture media for promoting the cell therapy technology" Under the chairmanship of Dr Tian Wenzhi, chairman and general manager of yimingongke biomedical technology (Shanghai) Co., Ltd., Dr Jiang Xinpo, legendary biology, Dr Liu Shuangsheng, quality president of Jinan Yiming Medical Technology Co., Ltd., and Dr Tan Chang, Jikai gene, jointly discussed the current situation and future development trend of car-t technology, the limitations of car-t product target selection, the change of evaluation mechanism, and the success of the product This paper discusses the hot issues in the process of industrialization and commercialization of cell therapy such as control and pricing Wonderful discussion contents and opinions won the applause of the audience In the new era of tumor immunotherapy driven by innovative drugs, Junshi biology has surpassed a large number of pharmaceutical enterprises in the attitude of "new born calves are not afraid of tigers" and won the first place in PD-1 drug market On the afternoon of August 18, Dr Feng Hui, chief operating officer of Junshi biology, took the lead in the lecture on "clinical strategy and biomarker exploration of tumor immunotherapy based on the differentiation of Chinese patients' characteristics" Dr Feng Hui has more than 10 years of experience in the biotechnology and drug discovery industries His experience covers many areas of drug development, including antibody discovery, protein engineering, and tumor immunotherapy Dr Feng Hui shared Junshi's practice and successful experience, and pointed out that it is faster and more differentiated to make innovative drugs in China As an innovative biopharmaceutical enterprise focusing on the field of tumor immunity and autoimmunity, Tianjing biology is highly focused on the development of innovative biopharmaceuticals with the potential of "Global Initiative" and "best in class" Dr Shen Huaqiong, President of Tianjing biological R & D and clinical development, shared the keynote speech of "R & D strategy and implementation of antitumor biological drugs" with the participants Dr Shen pointed out that clinical research and development should be clear about the market, intellectual property rights, medical system, etc at the same time, it needs to be clear about the regulatory requirements such as strategy, declaration node, etc Dr Tao Weikang, vice general manager of Jiangsu Hengrui Pharmaceutical Co., Ltd and CEO of the R & D center, has made a number of first discoveries and research achievements in the research and development of innovative drugs, the research of tumor immunity and new targets of anti-cancer, tumor cytology, especially the mechanism of tumor development Dr Tao Weikang shares the dry goods around "progress, challenges and Strategies of tumor immunotherapy" Talking about the prospect of tumor immunotherapy in the future, Dr Tao concluded that immunotherapy has opened a new door for anti-cancer, but the current progress is only the tip of the iceberg, theoretical research and clinical experience cannot keep up with the explosive growth in this field, and there is still a long way to go for the exploration of tumor immunotherapy in the future HPM is an innovative biomedical company operating globally, which is committed to providing innovative drugs focusing on tumor immunity and immune diseases for patients all over the world Dr Rong Yiping, director of early research and development of platinum medicine, has a wide range of background and experience in the field of tumor drug research and development Dr Rong brought dry goods sharing around "antibody research and development based on H2L2 and HCAB all human antibody mouse platform" Yimingongke biomedical technology (Shanghai) Co., Ltd is mainly engaged in the research and development of immunotherapy products for tumors Its products include monoclonal antibodies for immunomodulatory targets and NK cells that are armed with specific targets Dr Tian Wenzhi, chairman and general manager of yimingongke, made a wonderful share on "optimization of monoclonal antibody and double antibody technology in tumor immunotherapy" Special thanks for the careful preparation of the organizing committee, the sharing of more than 30 heavy speakers, the full coverage of 40 + authoritative media, and the gene medicine department of Shanghai Jikai